Cargando…

Drug therapy for myocarditis induced by immune checkpoint inhibitors

Immune checkpoint inhibitors (ICIs), including cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed cell death 1 (PD-1), and its ligand 1 (PD-L1), have improved the survival in multiple types of cancers; however, ICIs may cause cardiovascular toxicity. Although rare, ICI-mediated cardiotoxicity is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Yihao, Xu, Yizhou, Xu, Linhao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10248045/ https://www.ncbi.nlm.nih.gov/pubmed/37305530 http://dx.doi.org/10.3389/fphar.2023.1161243

Ejemplares similares

A model-informed approach to assess the risk of immune checkpoint inhibitor-induced autoimmune myocarditis
por: van der Vegt, Solveig A., et al.
Publicado: (2022)

Intrinsic Differences in Immune Checkpoint Inhibitor-Induced Myocarditis: A Retrospective Analysis of Real World Data
por: Lei, Yanna, et al.
Publicado: (2022)

Immune Checkpoint Inhibitor-Related Myositis Overlapping With Myocarditis: An Institutional Case Series and a Systematic Review of Literature
por: Nakagomi, Yuki, et al.
Publicado: (2022)

Pathophysiology of Immune Checkpoint Inhibitor-Induced Myocarditis
por: Jiménez-Alejandre, Rosa, et al.
Publicado: (2022)

Case Series of Steroid-Resistant Immune Checkpoint Inhibitor Associated Myocarditis: A Comparative Analysis of Corticosteroid and Tofacitinib Treatment
por: Wang, Cong, et al.
Publicado: (2021)

Intensified immunosuppressive therapy in patients with immune checkpoint inhibitor-induced myocarditis
por: Cautela, Jennifer, et al.
Publicado: (2020)

Plasma Exchange for Immune Checkpoint Inhibitor–Induced Myocarditis
por: Yogasundaram, Haran, et al.
Publicado: (2020)

Cisplatin Promotes the Efficacy of Immune Checkpoint Inhibitor Therapy by Inducing Ferroptosis and Activating Neutrophils
por: Zhou, Ziwei, et al.
Publicado: (2022)

How to Monitor Cardiac Complications of Immune Checkpoint Inhibitor Therapy
por: Spallarossa, Paolo, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors in Peripheral T-Cell Lymphoma
por: Chen, Xi, et al.
Publicado: (2022)

Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
por: Kumar, Vivek, et al.
Publicado: (2017)

Immune-Checkpoint Inhibitor-Induced Fulminant Myocarditis and Cardiogenic Shock
por: Itzhaki Ben Zadok, Osnat, et al.
Publicado: (2019)

Myocarditis Induced by Immune Checkpoint Inhibitors: Mechanisms and Therapeutic Prospects
por: Zou, Wenlu, et al.
Publicado: (2021)

Biomarkers for Immune Checkpoint Inhibitor–Induced Myocarditis: Caution Needed
por: Jaffe, Allan S.
Publicado: (2022)

Asymptomatic Immune Checkpoint Inhibitor-associated Myocarditis
por: Tanabe, Junya, et al.
Publicado: (2020)

The Strategies and Mechanisms of Immune Checkpoint Inhibitors for Brain Metastases in NSCLC
por: Li, Ji, et al.
Publicado: (2022)

Corrigendum: Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
por: Kumar, Vivek, et al.
Publicado: (2017)

Clinical Characteristics and Outcomes in Immune Checkpoint Inhibitor Therapy-Associated Myocarditis
por: Thakker, Ravi A., et al.
Publicado: (2021)

Immune Checkpoint Inhibitor-Induced Myocarditis vs. COVID-19 Vaccine-Induced Myocarditis—Same or Different?
por: Zornitzki, Lior, et al.
Publicado: (2022)

Immune-mediated hepatitis induced by immune checkpoint inhibitors: Current updates and future perspectives
por: Liu, Zherui, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors and Immune-Related Adverse Drug Reactions: Data From Italian Pharmacovigilance Database
por: Ruggiero, Rosanna, et al.
Publicado: (2020)

Resistance to immune checkpoint inhibitors in gastric cancer
por: Liu, Kai, et al.
Publicado: (2023)

Toxicity of Immune-Checkpoint Inhibitors in Hematological Malignancies
por: Hradska, Katarina, et al.
Publicado: (2021)

Clinical Insights Into Novel Immune Checkpoint Inhibitors
por: Lee, Jii Bum, et al.
Publicado: (2021)

Refractory right ventricular myocarditis induced by immune checkpoint inhibitor despite therapy cessation and immune suppression
por: Mohammad, Khan O., et al.
Publicado: (2023)

Prognosis of immune checkpoint inhibitors-induced myocarditis: a case series
por: Coustal, Cyrille, et al.
Publicado: (2023)

An Emergent Form of Cardiotoxicity: Acute Myocarditis Induced by Immune Checkpoint Inhibitors
por: Esposito, Roberta, et al.
Publicado: (2021)

Biomarker Trends, Incidence, and Outcomes of Immune Checkpoint Inhibitor–Induced Myocarditis
por: Vasbinder, Alexi, et al.
Publicado: (2022)

Combination immunomodulation for immune-checkpoint-inhibitor-associated myocarditis
por: Johnson, Douglas B., et al.
Publicado: (2023)

Cardiotoxicity Induced by Immune Checkpoint Inhibitors: A Pharmacovigilance Study From 2014 to 2019 Based on FAERS
por: Chen, Chenxin, et al.
Publicado: (2021)

Electrocardiographic features of immune checkpoint inhibitor associated myocarditis
por: Zlotoff, Daniel A, et al.
Publicado: (2021)

Musculoskeletal adverse events induced by immune checkpoint inhibitors: a large-scale pharmacovigilance study
por: Liu, Hao, et al.
Publicado: (2023)

TNF-α Inhibitors and Other Biologic Agents for the Treatment of Immune Checkpoint Inhibitor-Induced Myocarditis
por: Liu, Xiaohang, et al.
Publicado: (2022)

Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors
por: Shen, Pan, et al.
Publicado: (2021)

A Systematic Review of Myocarditis Induced by Immune Checkpoint Inhibitors: How Concerning Is the Most Common Cardiotoxicity of Immune Checkpoint Inhibitors?
por: Moradi, Ali, et al.
Publicado: (2023)

Fulminant myocarditis induced by immune checkpoint inhibitor nivolumab: a case report and review of the literature
por: Wang, Feifei, et al.
Publicado: (2021)

A preliminary study on drug switching strategy for second-line therapy after combination treatment of tyrosine kinase inhibitors and immune checkpoint inhibitors for unresectable hepatocellular carcinoma
por: Guan, Renguo, et al.
Publicado: (2022)

Adverse Effects and Toxicity of Immune Checkpoint Inhibitors For Patients With Urothelial Carcinoma
por: Wang, Di, et al.
Publicado: (2021)

Frequency of Immune Checkpoint Inhibitor-Induced Vasculitides: An Observational Study Using Data From the Japanese Adverse Drug Event Report Database
por: Kato, Koki, et al.
Publicado: (2022)

Mutations Status of Chemokine Signaling Pathway Predict Prognosis of Immune Checkpoint Inhibitors in Colon Adenocarcinoma
por: Lin, Anqi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_i0fn0qqmslmqoq0dhakg7i1ldq